Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations

Tal Ben-Ami*, Udo Kontny, Aurore Surun, Ines B. Brecht, Ricardo López Almaraz, Monica Dragomir, Apostolos Pourtsidis, Michela Casanova, Brice Fresneau, Gianni Bisogno, Dominik T. Schneider, Yves Reguerre, Ewa Bien, Teresa Stachowicz-Stencel, Gustaf Österlundh, Marc Wygoda, Geert O. Janssens, József Zsiros, Nina Jehanno, Herve J. BrisseLorenza Gandola, Hans Christiansen, Line Claude, Andrea Ferrari, Carlos Rodriguez-Galindo, Daniel Orbach

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Nasopharyngeal carcinoma (NPC) is a rare pediatric tumor. Collaborative studies performed over the last decades showed improved results compared to historical data, but standardized guidelines for diagnosis and management of pediatric NPC are still unavailable. This study presents a European consensus guideline for the diagnosis and treatment of pediatric NPC developed by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Main recommendations include induction chemotherapy with cisplatin and 5-flurouracil, concomitant chemoradiotherapy in advanced disease, and to consider maintenance treatment with interferon beta (IFN-β) for selected high-risk patients. Dose adjustments of radiotherapy based on response to induction chemotherapy may decrease the rates of long-term treatment-related complications that affect most of the survivors.

Original languageEnglish
Article numbere29018
JournalPediatric Blood and Cancer
Volume68 Suppl 4
Issue numberS4
DOIs
Publication statusPublished - Jun 2021

Keywords

  • adolescent
  • children
  • nasopharyngeal carcinoma
  • radiotherapy
  • rare tumors
  • recommendations

Fingerprint

Dive into the research topics of 'Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations'. Together they form a unique fingerprint.

Cite this